Actively Recruiting
Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)
Led by Karolinska Institutet · Updated on 2024-04-02
5160
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
K
Karolinska Institutet
Lead Sponsor
C
Capio Sankt Görans Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Prediabetes is associated to an increased risk of cardiovascular disease and mortality. Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of metformin to standard care has effects on the occurrence of cardiovascular events after acute myocardial infarction in patients with newly detected prediabetes (identified by oral glucose tolerance test, HbA1c or fasting glucose levels).
CONDITIONS
Official Title
Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 80 years who are Swedish citizens with a personal ID number
- Patients who have had an acute myocardial infarction (AMI)
- Newly diagnosed prediabetes confirmed by one of the following: HbA1c 42-47 mmol/mol; fasting plasma glucose 6.1-6.9 mmol/L; 2-hour post-load capillary glucose 8.9-12.1 mmol/L; 2-hour post-load venous plasma glucose 7.8-11.0 mmol/L; or elevated 2-hour glucose in the diabetes range without HbA1c diagnostic for diabetes
- No prior treatment with metformin or other glucose-lowering therapy
- Signed informed consent
You will not qualify if you...
- Type 1 diabetes or known type 2 diabetes
- Need for glucose-lowering treatment
- Acute conditions with high risk of volume depletion, circulatory shock, or hypoxia
- Serious illness other than cardiovascular disease with short life expectancy
- Kidney failure (eGFR less than 60 ml/min)
- Liver failure
- Cancer diagnosed within the last year
- Allergy or contraindication to metformin
- Alcohol or drug abuse
- Pregnancy or breastfeeding
- Women of childbearing potential without effective contraception during the study
- Previous hospitalization for lactic acidosis
- Expected inability to follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medicinkliniken, Ljungby Hospital
Ljungby, Sweden, 341 35
Actively Recruiting
Research Team
A
Anna Norhammar, MD, Prof.
CONTACT
V
Viveca Ritsinger, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here